Codexis, Inc. (NASDAQ:CDXS) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.00.

A number of research analysts have recently weighed in on CDXS shares. Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a report on Wednesday, March 14th. BidaskClub upgraded Codexis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 26th. HC Wainwright set a $12.00 price target on Codexis and gave the company a “buy” rating in a report on Monday, March 12th. ValuEngine upgraded Codexis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Finally, Stephens started coverage on Codexis in a report on Wednesday, May 16th. They set an “overweight” rating and a $16.00 price target on the stock.

In other Codexis news, Director David V. Smith sold 6,000 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $10.37, for a total value of $62,220.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John J. Nicols sold 7,207 shares of the business’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $15.35, for a total value of $110,627.45. Following the completion of the transaction, the chief executive officer now owns 1,079,886 shares in the company, valued at approximately $16,576,250.10. The disclosure for this sale can be found here. Insiders sold 222,842 shares of company stock worth $2,813,091 in the last 90 days. Corporate insiders own 11.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CDXS. Schwab Charles Investment Management Inc. grew its stake in Codexis by 52.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 84,581 shares of the biotechnology company’s stock valued at $707,000 after purchasing an additional 29,211 shares in the last quarter. Prescott Group Capital Management L.L.C. grew its stake in Codexis by 4.2% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 2,133,568 shares of the biotechnology company’s stock valued at $17,815,000 after purchasing an additional 86,356 shares in the last quarter. Wells Fargo & Company MN grew its stake in Codexis by 156.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,002,086 shares of the biotechnology company’s stock valued at $8,367,000 after purchasing an additional 611,289 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Codexis by 6.7% in the fourth quarter. Bank of New York Mellon Corp now owns 161,350 shares of the biotechnology company’s stock valued at $1,347,000 after purchasing an additional 10,079 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Codexis by 0.7% in the fourth quarter. BlackRock Inc. now owns 2,672,981 shares of the biotechnology company’s stock valued at $22,320,000 after purchasing an additional 18,193 shares in the last quarter. Hedge funds and other institutional investors own 65.89% of the company’s stock.

Shares of Codexis opened at $14.35 on Friday, MarketBeat.com reports. Codexis has a 1-year low of $4.55 and a 1-year high of $15.60. The company has a current ratio of 1.67, a quick ratio of 1.61 and a debt-to-equity ratio of 0.02. The firm has a market cap of $764.00 million, a PE ratio of -28.70 and a beta of -1.63.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Codexis had a negative net margin of 36.06% and a negative return on equity of 87.65%. The business had revenue of $14.04 million for the quarter, compared to analysts’ expectations of $13.50 million. equities research analysts anticipate that Codexis will post -0.27 EPS for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.